QLT names CEO
Executive Summary
QLT acting CEO Robert Butchofsky will fill the top post permanently. After an extensive search, the board decided to appoint Butchofsky based on his performance as acting chief since September 2005. Butchofsky joined QLT in 1998 and is credited with launching and commercializing the company's lead drug, the age-related macular degeneration injection Visudyne (vertaporfin). He previously worked for Allergan...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.